Skip to main content

Advertisement

SpringerLink
Log in

Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Objective: Rheumatoid arthritis is a chronic inflammatory autoimmune disease with proinflammatory cytokines involved in its pathogenesis. Recently in vitro as well as in vivo studies have shown that iloprost, a stable prostacyclin analogue, can reduce the release of these cytokines. This study was performed to further investigate the anti-inflammatory effects of iloprost by determining plasma adhesion molecules as markers of endothelial cell activation, and plasma thrombomodulin as a parameter of endothelial cell injury in patients with rheumatoid arthritis receiving oral iloprost therapy. Methods: Plasma thrombomodulin levels and the values of the plasma adhesion molecules VCAM-1 (vascular cell adhesion molecule 1), E-selectin (CD62E), and ICAM-1 (intercellular adhesion molecule 1, CD 54) were measured by ELISA during a 7-day period of treatment with orally-administered iloprost in 14 patients with active rheumatoid arthritis. Finally, the same parameters were determined at the end of the observation period (1 week after the end of therapy). In addition, the disease activity was measured using the DAS (disease activity score) as well as the patients’ self-assessed pain severity, and correlated with the changes of plasma adhesion molecule and thrombomodulin levels. Results The plasma levels of all three adhesion molecules as well as of thrombomodulin significantly decreased under therapy with oral iloprost. After 1 week (day 7 of therapy), the mean percent changes from day 0 were −20.1% for VCAM-1 (p=0.008), −21.2 for ICAM-1 (p=0.003), −24.6% for E-selectin (p=0.001), and −21.7% for thrombomodulin (p=0.003). This decrease lasted up to 1 week after the end of therapy in the case of VCAM-1 (p=0.023) and ICAM-1 (p=0.001). Further analysis of the results revealed additional significant correlations between different parameters of clinical disease activity, thrombomodulin and adhesion molecules. Conclusion This study showed hints towards clinical effects in patients with rheumatoid arthritis receiving oral iloprost therapy. Pathophysiologically, the decrease of adhesion molecules points at an immunomodulating effect of iloprost. The observed thrombomodulin-lowering effect of iloprost may indicate stabilisation of endothelial cell function by diminishing endothelial cell injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gay S, Gay RE, Koopman W (1993) Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis:two cellular mechanisms explain joint destruction. Ann Rheum Dis 52:S39–S47

    Google Scholar 

  2. Fitzgerald O, Bresnihan B (1995) Synovial membrane cellularity and vascularity. Ann Rheum Dis 54:511–515

    Google Scholar 

  3. Klareskog L, Ronnelid J, Holm G (1995) Immunopathogenesis and immunotherapy in rheumatoid arthritis:An area in transition. J Int Med 238:191–201

    Google Scholar 

  4. Szekynecz Z, Koch AE, Kunkel SL, Strieter RM (1998) Cytokines in rheumatoid arthritis. Potential targets for pharmacological interventions. Drug Ageing 12:377–390

    Google Scholar 

  5. Feldmann M, Brennan FM, Maini RN (1995) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440

    Article  Google Scholar 

  6. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244–247

    Article  CAS  PubMed  Google Scholar 

  7. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan, FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36:1681–1690

    Google Scholar 

  8. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumor necrosis factor ∀(cA2) in patients with rheumatoid arthritis. Lancet 344:1125–1127

    Article  Google Scholar 

  9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettinger RE, Cohan S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc-fusion protein. N Engl J Med 337:141–147

    Article  CAS  PubMed  Google Scholar 

  10. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M (1996) IL-1-Ra arthritis study group, Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39:1092–1101

    Google Scholar 

  11. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Roman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196–2204

    Article  CAS  PubMed  Google Scholar 

  12. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

    Article  CAS  PubMed  Google Scholar 

  13. Cronstein BN (1994) Adhesion molecules in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 6:300–304

    Google Scholar 

  14. Carlos TM, Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood 84:2068–2101

    CAS  PubMed  Google Scholar 

  15. Gearing AJH, Newman W (1993) Circulating adhesion molecules in disease. Immunol Today 14:506–512

    Google Scholar 

  16. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ (1992) Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, VCAM-1: pathological significance. Ann NY Acad Sci 667:324–331

    Google Scholar 

  17. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE (1993) Increased levels of circulating intercellular adhesion molecules 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 36:1098–1102

    CAS  PubMed  Google Scholar 

  18. Mason JC, Kapahi P, Haskard DO (1993) Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecules. Arthritis Rheum 36:519–527

    Google Scholar 

  19. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO (1993) Detection of circulating form of vascular cell adhesion molecule 1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 92:412–418

    CAS  PubMed  Google Scholar 

  20. Blann AD, McCollum CN, Steiner M, Jayson MIV (1995) Circulating adhesion molecules in inflammatory and atherosclerotic vascular disease. Immunol Today 16:251–252

    Article  Google Scholar 

  21. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor antibody in rheumatoid arthritis. Arthritis Rheum 39:1082–1091

    Google Scholar 

  22. Grant SM, Goa KL (1992) Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular procedures. Drugs 43:889–924

    Google Scholar 

  23. Jörres A, Luttmann W, Scholz P; Thierauch K-H, Gahl GM, Topley N, Frei U, Blitstein-Willinger E (1994) Specific inhibition of tumor necrosis factor in endotoxin-stimulated mononuclear leukocytes by prostacyclin analogue iloprost. Clin Intensive Care 5:296–302

    Google Scholar 

  24. Jörres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P (1997) Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 9:119–125

    Article  Google Scholar 

  25. Hildebrand M, Kraus C, Windt-Hanke F, Iffert B, Scheuermann H (1995) In vitro/in-vivo correlation of drug liberation with an extended release peroral dosage form for iloprost in man. Drug Dev Ind Pharm 21:2339–2353

    Google Scholar 

  26. Gao IK, Scholz P, Boehme MWJ, Norden C, Lemmel EM (2002) A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analogue iloprost: cytokine modulation, safety, and clinical effects. Rheumatol Int 22:45–51

    Article  Google Scholar 

  27. Esmon CT, Owen WG (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78:2249–2252

    Google Scholar 

  28. Dittman WA, Majerus PW (1990) Structure and function of thrombomodulin a natural anticoagulant. Blood 75:329–336

    Google Scholar 

  29. Ishii H, Yama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618–623

    Google Scholar 

  30. Sawada K, Yamamoto H, Yago H, Suehiro S (1992) A simple assay to detect endothelial cell injury; measurement of released thrombomodulin from cells. Exp Mol Pathol 57:116–123

    Article  Google Scholar 

  31. Boehme MWJ, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP (1996) Release of thrombomodulin from endothelial cells by concerted action of TNFα and neutrophils: in vivo and in vitro studies. Immunology 87:134–140

    Google Scholar 

  32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller J-G, Sharp J-T, Wilder RI, Hunter GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    CAS  PubMed  Google Scholar 

  33. Heijde van der DMFM, Hof van MA, Riel van PLCM, Leeuwen van MA, Rijswijk van HM, Putte van de LBA (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181

    Google Scholar 

  34. Riel van PLCM (1992) Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis. Br J Rheumatol 31:793–794

    Google Scholar 

  35. Bevilacqua MP (1993) Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11:767–804

    Article  Google Scholar 

  36. Gonzalez-Amaro R, Sanchez-Madrid F (1999) Cell adhesion molecules: selectins and integrins. Crit Rev Immunol 19:389–429

    Google Scholar 

  37. Seth R, Raymond FD, Makgoba MW (1991) Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 338:83–84

    Article  Google Scholar 

  38. Pigott R, Dillon LP, Hemingway IH, Gearing AJH (1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584–589

    CAS  PubMed  Google Scholar 

  39. Leeuwenberg JFM, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TMAA, Ahern TJ, Buurman WA (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549

    CAS  PubMed  Google Scholar 

  40. Hashimoto M, Shingu M, Ezaki I, Nobunga M, Minamihara M, Kato K, Sumioki H (1994) Production of soluble ICAM-1 from human endothelial cells induced by IL-1γ and TNF-α. Inflammation 18:163–173

    Google Scholar 

  41. Koch AE, Burriws JC, Haines GK, Carlos TM, Harlan JM, Leibovich SJ (1991) Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 64:313–320

    Google Scholar 

  42. Wilkinson LS, Edwards JCW, Poston RN, Haskard DO (1993) Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest 68:82–88

    Google Scholar 

  43. Hale LP, Martin ME, McCollum DE, Nunley JA, Springer TA, Singer KH, Haynes BF (1989) Immunhistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenviroment. Arthritis Rheum 32:22–30

    Google Scholar 

  44. Shinsaku S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483–1493

    Google Scholar 

  45. Furuzawa-Carballeda J, Alcover-Varela J (1999) Interleukin-8, interleukin-10, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression levels are higher in synovial tissue from patients with rheumatoid arthritis than in osteoarthritis. Scand J Immunol 50:215–222

    Article  Google Scholar 

  46. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077–1082

    Google Scholar 

  47. Smith MD, Slavotinek J, Au V, Weedon H, Parker A, Coleman M, Poberts-Thomson PJ, Ahern MJ (2001) Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. Rheumatology 40:965–977

    Article  Google Scholar 

  48. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliot MJ, McCloskey R, Feldmann M, Maini RN (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38–47

    Article  Google Scholar 

  49. Voskuyl AE, Martin S, Melchers L, Zwinderman AH, Weichselbraun I, Breedveld FC (1995) Levels of circulating intercellular adhesion molecule-1 and −3 but not circulating endothelial leukocyte adhesion molecule are increased in patients with rheumatoid vasculitis. Br J Rheumatol 34:311–315

    Google Scholar 

  50. Kolopp-Sarda MN, Guillemin F, Chary-Valckenaere I, Bene MC, Pourel J, Faure GC (2001) Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106 (V-CAM). Clin Exp Rheumatol 19:165–170

    Google Scholar 

  51. Machold KP, Kiener HP, Graininger W, Graininger WB (1993) Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 68:74–78

    Article  PubMed  Google Scholar 

  52. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL (1997) A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 36:164–169

    Article  Google Scholar 

  53. Tokuhira M, Hosaka S, Volin MV, Haines GK, Katschke KJ, Kim S, Koch AE (2000) Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 43:1122–1133

    Article  Google Scholar 

  54. Kuuliala A, Eberhardt K, Takala A, Kautainen H, Repo H, Leirisalo-Repo M (2002) Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five-year study. Ann Rheum Dis 61:242–246

    Article  Google Scholar 

  55. Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ (1998) Soluble cell adhesion molecules P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheum 27:296–299

    Article  Google Scholar 

  56. Grundmann HJ, Hähnle U, Hegenscheid B, Sahlmäller G, Bienzle U, Blitstein-Willinger E (1992) Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J Infect Dis 165:501–505

    Google Scholar 

  57. Darius H, Veit K, Binz C, Fisch A, Meyer J (1995) Diminished inhibition of adhesion molecule expression in prostacyclin receptors desensitized human platelets. Agents Actions Suppl 45:77–83

    Google Scholar 

  58. Fischer CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP (1987) Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1 on human platelets function. J Lab Clin Med 109:184–190

    Google Scholar 

  59. Della Bella S, Molteni M, Compasso S, Zulian C, Vanoli M, Scorza R (1997) Differential effects of cyclooxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids 56:177–184

    Article  Google Scholar 

  60. Czeslick EG, Simm A, Ground S, Sliber RE, Sablotzki A (2003) Inhibition of intracellular tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 33:1013–1017

    Article  Google Scholar 

  61. Mazzone A, Faggioli P, Cusa C, Stefanin C, Rondena M, Morelli B (2002) Effects of iloprost on adhesion molecules and F1+2 in peripheral ischemia. Eur J Clin Invest 32:882–888

    Article  Google Scholar 

  62. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostag Other Lip Mediat 65:73–83

    Article  Google Scholar 

  63. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N (1994) Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 101:109–113

    Google Scholar 

  64. Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL (1996) Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener’s granulomatosis and other systemic vasculitides. Am J Med 101:387–394

    Article  CAS  PubMed  Google Scholar 

  65. Boehme MWJ, Raeth U, Galle PR, Stremmel W, Scherbaum WA (2000) Serum thrombomodulin—a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 119:189–195

    Google Scholar 

  66. Candela M, Pansoni A, Jannino L, Menditto VG, Natalini M, Ravaglia F, DaLio L, Scorza R, Gabrielli A, Danieli G (2001) Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine. Ann Ital Med Int 16:170–174

    Google Scholar 

  67. Vayssairat M (1996) Controlled multicenter double blind trial on an oral analog of prostacyclin in the treatment of primary Raynaud’s phenomenon. J Rheumatol 23:1917–1920

    Google Scholar 

  68. Hayakawa T, Shouzu A, Nishikawa M, Miyake Y, Shimizu H, Omoto S, Inada M (2000) Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients. Arzneimittelforschung 20:535–538

    Google Scholar 

  69. Moncada S, Higgs EA, Vane JR (1977) Human arterial and venous tissue generates prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1:18–20

    Article  Google Scholar 

  70. Moncada S (1982) Prostacyclin and arterial wall biology. Arteriosclerosis 2:193–202

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dep. of Internal Medicine IV, University of Heidelberg, Bergheimer Str. 58, D-69115, Heidelberg, Germany

    Michael W. J. Boehme

  2. Rheumatology Practice, Dossenheimer Landstr. 100, 69121, Heidelberg, Germany

    Ino K. Gao

  3. Schering AG, Sellerstr. 31, 13342, Berlin, Germany

    Cornelia Norden

  4. Max Grundig Clinic, Bühlerhöhe, Schwarzwaldhochstr. 1, 77815, Bühl, Germany

    Ernst-Martin Lemmel

  5. Public Health Office, Parkstr. 4, D-71034, Böblingen, Germany

    Michael W. J. Boehme

Authors
  1. Michael W. J. Boehme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ino K. Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cornelia Norden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ernst-Martin Lemmel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. J. Boehme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boehme, M.W.J., Gao, I.K., Norden, C. et al. Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results. Rheumatol Int 26, 340–347 (2006). https://doi.org/10.1007/s00296-004-0563-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-004-0563-9

Keywords

Search

Navigation